Dr. Bekaii-Saab Discusses the Next Steps With Regorafenib in CRC

Video

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the next steps following for regorafenib (Stivarga) in colorectal cancer (CRC).

Tanios Bekaii-Saab, MD, professor of medicine, Mayo Clinic, discusses the next steps for regorafenib (Stivarga) in colorectal cancer (CRC).

Physicians are working on confirming the results of the REVERCE study in the United States, which revealed the superiority of sequencing regorafenib before cetuximab (Erbitux) in patients with metastatic CRC who progressed on standard chemotherapy, says Bekaii-Saab.

Physicians are building a proposal asking the same question of patients with metastatic CRC that a Japanese study asked regarding the sequencing of regorafenib in a United States population. This is to better understand whether moving regorafenib to an earlier line of therapy, before EGFR inhibitors, may indeed improve outcomes—similar to what was seen in the Japanese study.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD